NCT07150338

Outcome of Use of a Novel Modulator of Oxidative Phosphorylation on Kidney Function in Patients With Progressive Chronic Kidney Disease

Outcome of Use of a Novel Modulator of Oxidative Phosphorylation on Kidney Function in Patients With Chronic Kidney Disease

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 45 (actual)
• Sponsor: Neukidney Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Outcome of use of a novel Modulator of Oxidative Phosphorylation on kidney function in patients with Chronic Kidney Disease

Detailed description

QRX-3 ( Eseronate ) is a formulated drug designed to supply and optimize NAD+ mitochondrial availability in order to target the loss of nephrons via renal fibrosis and tubular senescence of the kidney cells by enhancing the mitochondrial activity of these cells via the NAD/NAD+ redox pathway as well as reduce the presence of fibrogenic intracellular inflammatory markers . This novel drug therapy stabilized the intracellular oxidative phosphorylation process a pathway mechanism that is dysregulated or abnormal in the ongoing renal tubular cell injury and damage in chronic kidney disease. In this study the investigators evaluate the effect of intervention with this novel drug therapy on a chronic kidney disease CKD population with slowly progressively declining renal function.

Conditions

• Chronic Kidney Disease (Stage 3-4)
• Chronic Kidney Disease (Stages 4 and 5)
• Proteinuria

Interventions

Type	Name	Description
DRUG	QRX-3	Compounded new drug regime
DRUG	Eseronate	Neukidney innovative drug

Timeline

• Start date: 2021-05-20
• Primary completion: 2022-04-20
• Completion: 2022-11-20
• First posted: 2025-09-02
• Last updated: 2025-09-08

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study